{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:01:44Z","timestamp":1777680104886,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"44","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.vaccine.2016.08.089","type":"journal-article","created":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T16:00:41Z","timestamp":1473782441000},"page":"5344-5351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations"],"prefix":"10.1016","volume":"34","author":[{"given":"Anne-Marie C.","family":"Andersson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emeline","family":"Ragonnaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly E.","family":"Seaton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheetal","family":"Sawant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Folgori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Colloca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celia","family":"Labranche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Montefiori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia D.","family":"Tomaras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Holst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2016.08.089_b0005","doi-asserted-by":"crossref","first-page":"S309","DOI":"10.1086\/655653","article-title":"Viral evolution and escape during acute HIV-1 infection","volume":"202","author":"Boutwell","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.08.089_b0010","doi-asserted-by":"crossref","first-page":"e1002200","DOI":"10.1371\/journal.ppat.1002200","article-title":"Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies","volume":"7","author":"Ma","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2016.08.089_b0015","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1084\/jem.20122824","article-title":"Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies","volume":"210","author":"McGuire","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2016.08.089_b0020","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nri3516","article-title":"Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning","volume":"13","author":"Kwong","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2016.08.089_b0025","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/COH.0000000000000153","article-title":"HIV broadly neutralizing antibody targets","volume":"10","author":"Wibmer","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.vaccine.2016.08.089_b0030","doi-asserted-by":"crossref","first-page":"310rv7","DOI":"10.1126\/scitranslmed.aac7732","article-title":"Immune correlates of vaccine protection against HIV-1 acquisition","volume":"7","author":"Corey","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2016.08.089_b0035","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2016.08.089_b0040","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/infdis\/jiu003","article-title":"Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles","volume":"210","author":"Goepfert","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.08.089_b0045","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.virol.2007.10.033","article-title":"Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA","volume":"372","author":"Wyatt","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2016.08.089_b0050","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/bit.24342","article-title":"Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors","volume":"109","author":"Cottingham","year":"2012","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2016.08.089_b0055","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1128\/JVI.00542-07","article-title":"Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles","volume":"81","author":"Wang","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.08.089_b0060","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1126\/science.aaa9804","article-title":"HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein","volume":"349","author":"Chen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2016.08.089_b0065","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1099\/vir.0.82727-0","article-title":"Rapid and sustained CD4(+) T-cell-independent immunity from adenovirus-encoded vaccine antigens","volume":"88","author":"Holst","year":"2007","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2016.08.089_b0070","doi-asserted-by":"crossref","first-page":"115ra2","DOI":"10.1126\/scitranslmed.3002925","article-title":"Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species","volume":"4","author":"Colloca","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2016.08.089_b0075","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.virol.2006.04.043","article-title":"A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses","volume":"353","author":"Liao","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2016.08.089_b0080","doi-asserted-by":"crossref","first-page":"e18556","DOI":"10.1371\/journal.pone.0018556","article-title":"High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice","volume":"6","author":"Kim","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.08.089_b0085","doi-asserted-by":"crossref","first-page":"e55435","DOI":"10.1371\/journal.pone.0055435","article-title":"Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived from the bonobo Pan paniscus","volume":"8","author":"Vitelli","year":"2013","journal-title":"PLoS ONE"},{"issue":"Pt A","key":"10.1016\/j.vaccine.2016.08.089_b0090","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0091-679X(08)60603-2","article-title":"Use of recombinant adenovirus for metabolic engineering of mammalian cells","volume":"43","author":"Becker","year":"1994","journal-title":"Methods Cell Biol"},{"key":"10.1016\/j.vaccine.2016.08.089_b0095","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.vaccine.2008.12.051","article-title":"A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines","volume":"27","author":"Peruzzi","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.08.089_b0100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.virol.2007.07.017","article-title":"GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA\/MVA immunodeficiency virus vaccine","volume":"369","author":"Lai","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2016.08.089_b0105","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1128\/AAC.46.6.1896-1905.2002","article-title":"Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy","volume":"46","author":"Wei","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2016.08.089_b0110","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1600-0684.1992.tb00589.x","article-title":"Shared antigenic epitopes of the major core proteins of human and simian immunodeficiency virus isolates","volume":"21","author":"Higgins","year":"1992","journal-title":"J Med Primatol"},{"key":"10.1016\/j.vaccine.2016.08.089_b0115","doi-asserted-by":"crossref","first-page":"e101863","DOI":"10.1371\/journal.pone.0101863","article-title":"HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities","volume":"9","author":"Seaton","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.08.089_b0120","doi-asserted-by":"crossref","first-page":"12449","DOI":"10.1128\/JVI.01708-08","article-title":"Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia","volume":"82","author":"Tomaras","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.08.089_b0125","doi-asserted-by":"crossref","first-page":"228ra39","DOI":"10.1126\/scitranslmed.3007730","article-title":"Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination","volume":"6","author":"Yates","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2016.08.089_b0130","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/mi.2012.107","article-title":"HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life","volume":"6","author":"Yates","year":"2013","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2016.08.089_b0135","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","article-title":"Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2016.08.089_b0140","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature10373","article-title":"Broad neutralization coverage of HIV by multiple highly potent antibodies","volume":"477","author":"Walker","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2016.08.089_b0145","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.immuni.2014.04.008","article-title":"Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers","volume":"40","author":"Blattner","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2016.08.089_b0150","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1128\/JVI.67.7.3978-3988.1993","article-title":"Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding","volume":"67","author":"Thali","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.08.089_b0155","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/978-1-59745-170-3_26","article-title":"Measuring HIV neutralization in a luciferase reporter gene assay","volume":"485","author":"Montefiori","year":"2009","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2016.08.089_b0160","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/j.vaccine.2015.06.087","article-title":"An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4\u20131BBL leads to delayed tumor progression","volume":"34","author":"Ragonnaud","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.08.089_b0165","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1172\/JCI22953","article-title":"Magnetic resonance spectroscopy reveals that activated monocytes contribute to neuronal injury in SIV neuroAIDS","volume":"115","author":"Williams","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2016.08.089_b0170","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1128\/JVI.68.4.2362-2370.1994","article-title":"Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques","volume":"68","author":"Reimann","year":"1994","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.08.089_b0175","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1126\/science.7973652","article-title":"Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody","volume":"266","author":"Burton","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2016.08.089_b0180","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1128\/JVI.76.14.7293-7305.2002","article-title":"The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120","volume":"76","author":"Sanders","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.08.089_b0185","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1128\/JVI.70.2.1100-1108.1996","article-title":"Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1","volume":"70","author":"Trkola","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.08.089_b0190","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1743-8977-8-18","article-title":"Distribution of silver in rats following 28days of repeated oral exposure to silver nanoparticles or silver acetate","volume":"8","author":"Loeschner","year":"2011","journal-title":"Part Fibre Toxicol"},{"key":"10.1016\/j.vaccine.2016.08.089_b0195","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J Roy Stat Soc: Ser B (Methodol)"},{"key":"10.1016\/j.vaccine.2016.08.089_b0200","doi-asserted-by":"crossref","first-page":"6462","DOI":"10.1128\/JVI.00383-15","article-title":"Comparison of immunogenicity in rhesus macaques of transmitted-founder, HIV-1 group M consensus, and trivalent mosaic envelope vaccines formulated as a DNA Prime, NYVAC, and envelope protein boost","volume":"89","author":"Hulot","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.08.089_b0205","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1128\/JVI.02297-12","article-title":"Antigenicity and immunogenicity of transmitted\/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1","volume":"87","author":"Liao","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.08.089_b0210","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0960-9822(06)00331-9","article-title":"Cryo-electron microscopy reveals ordered domains in the immature HIV-1 particle","volume":"7","author":"Fuller","year":"1997","journal-title":"Curr Biol"},{"key":"10.1016\/j.vaccine.2016.08.089_b0215","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1089\/0889222041217428","article-title":"Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component","volume":"20","author":"Wyatt","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2016.08.089_b0220","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1128\/JVI.76.6.2683-2691.2002","article-title":"Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein","volume":"76","author":"Edwards","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2016.08.089_b0225","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12977-015-0210-4","article-title":"Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity","volume":"12","author":"Sliepen","year":"2015","journal-title":"Retrovirology"},{"key":"10.1016\/j.vaccine.2016.08.089_b0230","doi-asserted-by":"crossref","first-page":"aac4223","DOI":"10.1126\/science.aac4223","article-title":"HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers","volume":"349","author":"Sanders","year":"2015","journal-title":"Science"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16307988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16307988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T10:08:55Z","timestamp":1718791735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16307988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":46,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0264410X16307988"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.08.089","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.08.089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}